Wen H, Wang HY, He X, Wu CI. On the low reproducibility of most cancers research. Natl Sci Rev. 2018;5:619–24. https://doi.org/10.1093/nsr/nwy021
Kim D, Hasford J. Redundant trials will be prevented, if the EU scientific trial regulation is utilized duly. BMC Med Ethics. 2020;21:107. https://doi.org/10.1186/s12910-020-00536-9
Ioannidis JPA. The mass manufacturing of redundant, deceptive, and conflicted systematic evaluations and meta-analyses. Milbank Q. 2016;94:485–514. https://doi.org/10.1111/1468-0009.12210
Jia Y, Wen J, Qureshi R, Ehrhardt S, Celentano DD, Wei X, et al. Impact of redundant scientific trials from mainland China evaluating statins in sufferers with coronary artery illness: cross-sectional examine. BMJ. 2021;372:n48. https://doi.org/10.1136/bmj.n48
Da Silva JAT. Points and challenges to reproducibility of most cancers analysis: a commentary. Future Oncol. 2022;18:1417–22. https://doi.org/10.2217/fon-2021-1378
DeVita VT, Chu E. A historical past of most cancers chemotherapy. Most cancers Res. 2008;68:8643–53. https://doi.org/10.1158/0008-5472.CAN-07-6611
Huh HD, Kim S. Historical past of radiation remedy know-how. Prog Med Phys. 2020;31:124–34. https://doi.org/10.14316/pmp.2020.31.3.124
Abshire D, Lang MK. The evolution of radiation remedy in treating most cancers. Semin Oncol Nurs. 2018;34:151–7. https://doi.org/10.1016/j.soncn.2018.03.006
Haslam A, Prasad V. Estimation of the proportion of us sufferers with most cancers who’re eligible for and reply to checkpoint inhibitor immunotherapy medication. JAMA Netw Open. 2019;2:e192535. https://doi.org/10.1001/jamanetworkopen.2019.2535
Choi G, Shin G, Bae SJ. Worth and prejudice? The worth of chimeric antigen receptor (CAR) T-cell remedy. Int J Environ Res Public Well being. 2022;19:12366. https://doi.org/10.3390/ijerph191912366
Kurtovic-Kozaric A, Vranic S, Kurtovic S, Hasic A, Kozaric M, Granov N, et al. Lack of entry to focused most cancers therapy modalities within the creating world within the period of precision drugs: real-life classes from Bosnia. J Glob Oncol. 2018;4:1–5. https://doi.org/10.1200/JGO.2016.008698
Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP, et al. Kinase-targeted most cancers therapies: progress, challenges and future instructions. Mol Most cancers. 2018;17:1–20. https://doi.org/10.1186/S12943-018-0804-2.
Tanda ET, Vanni I, Boutros A, Andreotti V, Bruno W, Ghiorzo P, et al. Present state of goal therapy in BRAF mutated melanoma. Entrance Mol Biosci. 2020;7:154 https://doi.org/10.3389/fmolb.2020.00154
Bédouelle E, Nguyen JM, Varey E, Khammari A, Dreno B. Ought to focused remedy be continued in braf-mutant melanoma sufferers after full remission? Dermatology. 2022;238:517–26. https://doi.org/10.1159/000518718
Mason S, Tovey P, Lengthy AF. Evaluating complementary drugs: methodological challenges of randomised managed trials. Br Med J. 2002;325:832–4. https://doi.org/10.1136/bmj.325.7368.832
Ropers HH. Single gene issues come into focus—once more. Dialogues Clin Neurosci. 2010;12:95. https://doi.org/10.31887/10.31887/dcns.2010.12.1/hhropers
Shi C, de Wit S, Učambarlić E, Markousis-Mavrogenis G, Screever EM, Meijers WC, et al. Multifactorial illnesses of the center, kidneys, lungs, and liver and incident most cancers: epidemiology and shared mechanisms. Cancers. 2023;15:729. https://doi.org/10.3390/cancers15030729
Kesić S. Techniques biology, emergence and antireductionism. Saudi J Biol Sci. 2016;23:584–91. https://doi.org/10.1016/j.sjbs.2015.06.015
Freeman J. In the direction of a definition of holism. Br J Gen Pract. 2005;55:154.
Lim B, Lin Y, Navin N. Advancing most cancers analysis and drugs with single-cell genomics. Most cancers Cell. 2020;37:456–70. https://doi.org/10.1016/j.ccell.2020.03.008
Wang R, Li J, Zhou X, Mao Y, Wang W, Gao S, et al. Single-cell genomic and transcriptomic landscapes of main and metastatic colorectal most cancers tumors. Genome Med. 2022;14:93 https://doi.org/10.1186/s13073-022-01093-z
Scott EC, Baines AC, Gong Y, Moore R, Pamuk GE, Saber H, et al. Developments within the approval of most cancers therapies by the FDA within the twenty-first century. Nat Rev Drug Discov. 2023;22:625–40. https://doi.org/10.1038/s41573-023-00723-4
Siegel RL, Miller KD, Wagle NS, Jemal A. Most cancers statistics, 2023. CA Most cancers J Clin. 2023;73:17–48. https://doi.org/10.3322/caac.21763
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. International Most cancers Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 nations. CA Most cancers J Clin. 2021;71:209–49. https://doi.org/10.3322/CAAC.21660
Goyal R, Wassie MM, Winter J, Lathlean TJ, Younger GP, Symonds EL. Progress within the area of noninvasive diagnostics for colorectal most cancers: a scientific evaluation for the accuracy of blood-based biomarkers for detection of superior pre-cancerous lesions. Professional Rev Mol Diagn. 2023;23:1233–50. https://doi.org/10.1080/14737159.2023.2290646
Lin MJ, Svensson-Arvelund J, Lubitz GS, Marabelle A, Melero I, Brown BD, et al. Most cancers vaccines: the following immunotherapy frontier. Nat Most cancers. 2022;3:911–26. https://doi.org/10.1038/S43018-022-00418-6
Park M, Leahey E, Funk RJ. Papers and patents have gotten much less disruptive over time. Nature. 2023;613:138–44. https://doi.org/10.1038/s41586-022-05543-x
Lin A, Giuliano CJ, Palladino A, John KM, Abramowicz C, Yuan ML, et al. Off-target toxicity is a standard mechanism of motion of most cancers medication present process scientific trials. Sci Transl Med. 2019;11:eaaw8412. https://doi.org/10.1126/SCITRANSLMED.AAW8412
Foulkes I, Sharpless NE. Most cancers grand challenges: embarking on a brand new period of discovery. Most cancers Discov. 2021;11:23–7. https://doi.org/10.1158/2159-8290.CD-20-1657
Harris E. Most cancers moonshot plan introduced. JAMA. 2023;329:1443 https://doi.org/10.1001/JAMA.2023.6252
Most cancers Moonshot Progress – NCI n.d. https://www.most cancers.gov/analysis/key-initiatives/moonshot-cancer-initiative/progress (accessed 4 Dec 2023).
Mavrogenis AF, Quaile A, Scarlat MM. The great, the dangerous and the impolite peer-review. Int Orthop. 2020;44:413–5. https://doi.org/10.1007/S00264-020-04504-1
Barroga E. Modern methods for peer evaluation. J Korean Med Sci. 2020;35:e138 https://doi.org/10.3346/JKMS.2020.35.E138
Nature will publish peer evaluation reviews as a trial. Nature. 2020;578:8. https://doi.org/10.1038/D41586-020-00309-9.
